Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.

Blood - 4 Jul 2024

Zhao Yaqi, Short Nicholas J, Kantarjian Hagop M, Chang Ti-Cheng, Ghate Pankaj S, Qu Chunxu, Macaron Walid, Jain Nitin, Thakral Beenu, Phillips Aaron H, Khoury Joseph, Garcia-Manero Guillermo, Zhang Wenchao, Fan Yiping, Yang Hui, Garris Rebecca S, Nasr Lewis F, Kriwacki Richard W, Roberts Kathryn G, Konopleva Marina, Jabbour Elias J, Mullighan Charles G

Abstract excerpt

ABSTRACT: Inotuzumab ozogamicin (InO) is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells. In a retrospective cohort of InO-treated patients with B-cell acute lymphoblastic leukemia, we sought to understand the genomic determinants of the response and resistance to InO. Pre- and post-InO-treated patient samples were analyzed by whole genome, exome, and/or transcriptome sequencing....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Adolescent

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Polyomavirus and related diseases

Share to Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Share to Synthesis and Biological Evaluation

Source

Open in PubMed Open full text

Identifiers

PMID: 38551807
DOI: 10.1182/blood.2024023930
PMCID: PMC11251222

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.PMID 38551807Read ↗

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLSemantic proximity Read ↗

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicinSemantic proximity Read ↗

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Case Report: Immune-driven clonal selection underlying lineage switch from B-Precursor acute lymphoblastic leukemia to acute myeloid leukemia following inotuzumab ozogamicin.Semantic proximity Read ↗

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.Semantic proximity Read ↗

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.Semantic proximity Read ↗

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53Semantic proximity Read ↗

Five‐Year Real‐World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B‐Cell Precursor Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Mechanisms of drug resistance in acute lymphoblastic leukemia.Semantic proximity Read ↗

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemiaSemantic proximity Read ↗

Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B-acute lymphoblastic leukaemia.Semantic proximity Read ↗

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.